Related Experiment Video
Updated: Jun 17, 2025

08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
31.7K
Cortical inexcitability in ALS: correlating a clinical phenotype
Nathan Pavey1,2, Andrew Hannaford1,2, Mana Higashihara3
1The University of Sydney, Sydney, New South Wales, Australia.
Journal of Neurology, Neurosurgery, and Psychiatry
|August 13, 2024
Summary
Cortical inexcitability in amyotrophic lateral sclerosis (ALS) is linked to a more severe phenotype, including earlier onset and greater motor decline. However, it did not impact patient survival in this study.
Area of Science:
- Neurology
- Neurophysiology
- Motor Neuron Diseases
Background:
- Cortical inexcitability is an understudied aspect of upper motor neuron (UMN) dysfunction in amyotrophic lateral sclerosis (ALS).
- This study investigated the characteristics and impact of cortical inexcitability in a large ALS patient cohort.
Purpose of the Study:
- To identify and characterize cortical inexcitability in ALS patients.
- To compare demographic, clinical, and survival data of inexcitable ALS patients with normal or hyperexcitable cohorts.
- To assess the influence of cortical inexcitability on ALS phenotype and survival.
Main Methods:
- Utilized threshold-tracking transcranial magnetic stimulation (TMS) to measure short interval intracortical inhibition (SICI).
- Classified 417 ALS patients into three groups: inexcitable, hyperexcitable (SICI≤5.5%), and normal cortical excitability (SICI>5.5%).
- Conducted clinical phenotyping, neurophysiological assessment of lower motor neuron (LMN) function, and survival analysis.
Main Results:
- 26.4% of ALS patients exhibited cortical inexcitability.
- Cortical inexcitability correlated with younger age of onset, advanced disease stage, higher UMN scores, and lower functional/strength scores.
- Survival was comparable across groups, though riluzole use was lower in the inexcitable group.
Conclusions:
- Cortical inexcitability defines an ALS phenotype with pronounced UMN signs, accelerated motor and functional decline, and earlier onset.
- Findings aid in patient management and stratification for clinical trials.
- Further research may explore targeted interventions for this specific ALS subtype.

